A Phase III trial of inhibitory effect of metachronous gastric cancer by Helicobacter pylori eradication for patients after endoscopic submucosal dissectio
Not Applicable
- Conditions
- Early gastric cancer
- Registration Number
- JPRN-UMIN000018403
- Lead Sponsor
- Shizuoka Cancer Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 1000
Inclusion Criteria
Not provided
Exclusion Criteria
(1) synchronous or metachronous (within 5 years) malignancy other than carcinoma in situ (2) Infectious disease with systemic therapy indicated. (3) Body temperature of 38 or more degrees Celsius. (4) pregnant or breast-feeding women (5) Severe psychiatric disease. (6) Continuous systemic steroid therapy. (7) Unstable angina pectoris, or history of myocardial infarction within six months. (8) Poorly controlled hypertension. (9) Severe respiratory disease requiring continuous oxygen therapy. (10)Penicillin allergy (11) Poorly controlled diabetes mellitus in spite of continuous use of insulin.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The proportion of 5 -year cumulative metachronous gastric cancer
- Secondary Outcome Measures
Name Time Method The proportion of 5 -year cumulative metachronous gastric cancer according to pepsinogen levels The proportion of annual cumulative metachronous gastric cancer Overall survival time Disease free survival time The proportion of the incidence of reflux esophagitis The proportion of exacerbation of reflux esophagitis